This is a routine annual meeting with no signs of shareholder activism or governance disputes. The recent board appointment of John Gallina, a former CFO of Elevance Health, suggests a focus on financial and audit expertise. Traders should monitor for any future filings indicating activist involvement or governance challenges, but this proxy indicates stable management control.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 6 $73.24entry
- T+1 · 7mo ago +5.87%α +5.81% · $77.54
- T+5 · 7mo ago +5.70%α +1.56% · $77.41
- T+20 · 7mo ago +11.99%α +3.01% · $82.02
- T+60 · 5mo ago +43.11%α +29.93% · $104.81
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CVS Health is holding its 2026 annual shareholder meeting to vote on director elections, auditor ratification, executive compensation, and a shareholder proposal to lower the threshold for shareholder action by written consent. This filing follows the recent addition of John Gallina to the board, indicating continuity in governance.
Key Financial Metrics
Key Facts
- Annual meeting scheduled for May 14, 2026, to vote on 13 director nominees, auditor ratification, executive compensation (Say on Pay), and a new incentive plan.
- Shareholders are asked to vote against a proposal to reduce the threshold for shareholder action by written consent.
- Recent 8-K filing confirms John Gallina's election to the board on March 19, 2026, as an independent director and member of the Audit Committee.
- The filing is a standard annual proxy statement with no major governance changes or contentious issues.
Financial Impact
No direct financial impact from this filing. The vote on executive compensation and incentive plans relates to ongoing corporate governance.
Risk Factors
- Potential for future shareholder activism if governance or performance issues arise.
- Regulatory or compliance risks related to executive compensation disclosures.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001308179-26-000202 |
| Document: 0001308179-26-000202-index-headers.html | 0001308179-26-000202 |
| Document: 0001308179-26-000202-index.html | 0001308179-26-000202 |
| Document: 0001308179-26-000202.txt | 0001308179-26-000202 |
Track record
25 reports on CVS
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +32.33% at T+60 after the Apr 8, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 13, 20264d ago Court Ruling Neutral 3/10 No price data
- Nov 6, 202610d ago Insider Buy Bullish 4/10 Entry $85.25 Now $88.59 +3.92% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 6/10 Entry $79.96 Now $88.59 +10.79% settles Dec 3
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $79.96 Now $88.59 +10.79% settles Dec 3
- Oct 26, 202621d ago Institutional Cluster Neutral 3/10 Entry $92.53 Now $88.59 −4.26% settles Nov 23
- Oct 15, 20264w ago Press Release Neutral 2/10 Entry $92.58 to $89.79 Now $88.59 −4.31% ▼ −3.01% −1.11% vs SPY
- Sep 30, 20266w ago Press Release Neutral 2/10 Entry $85.20 to $90.33 Now $88.59 +3.98% ▲ +6.02% +5.32% vs SPY
- Aug 5, 202614w ago 8-K Bullish 8/10 Entry $99.12 to $97.23 Now $88.59 −10.62% ▼ −1.91% −1.31% vs SPY
- Jul 10, 202618w ago Press Release Neutral 2/10 Entry $104.15 to $95.46 Now $88.59 −14.94% ▼ −8.35% −10.77% vs SPY
- Jun 29, 202620w ago Court Ruling Bullish 5/10 Entry $103.58 to $107.74 Now $88.59 −14.47% ▲ +4.02% +4.30% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers